𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Survival of Parkinson's disease patients in a large prospective cohort of male health professionals

✍ Scribed by Honglei Chen; Shumin M. Zhang; Michael A. Schwarzschild; Miguel A. Hernán; Alberto Ascherio


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
92 KB
Volume
21
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Parkinson's disease (PD) patients have higher mortality than individuals without PD. However, most of the previous studies were based on prevalent cases and few examined the potential effects of duration and smoking on the survival of PD patients. We compared the survival experience of 288 men with incident PD diagnosed between 1986 and 2000 with that of 51,012 men free of PD in the Health Professionals Follow‐up Study. As of January 2002, 92 deaths occurred among PD cases and 8,485 among men without PD. After controlling for age, men with PD had 60% higher mortality than those without PD (95% CI: 1.3–2.0). PD mortality was strongly related to disease duration: compared with men without PD, the age‐adjusted relative risk for PD patients was 1.1 during the first 5 years from diagnosis, 2.3 from 5 to 10 years, and 3.5 after 10 years (P < 0.0001 for trend). As expected, cigarette smoking was strongly and positively associated with total mortality among men free of PD (comparing >30 pack‐years vs. never smokers, relative risk, 2.0; P < 0.0001 for trend), but this association was not observed among PD patients (RR: 1.0; P = 0.95 for trend). This study confirms that PD patients have a higher mortality than individuals without PD and that the excess mortality increases with disease duration. However, smoking seems to impose little additional risk among PD patients in this large cohort of health professionals. © 2006 Movement Disorder Society


📜 SIMILAR VOLUMES


A comparison of treatment thresholds in
✍ Connie Marras; Anthony E. Lang; Shirley W. Eberly; David Oakes; Stanley Fahn; St 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) and Parkinson Research Examination of CEP‐1347 Trial (PRECEPT) were two clinical trials of potential disease‐modifying agents for Parkinson's disease that used the time to reaching disability sufficient to require d

PINK1 mutations in a Brazilian cohort of
✍ Clecio Godeiro-Junior; Patricia M. de Carvalho-Aguiar; Andre C. Felício; Orlando 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 1 views

## Abstract Data on the frequency of __PINK1__ mutations in Brazilian patients with early‐onset Parkinson's disease (EOPD) are lacking. The aim of this report was to investigate mutations of the __PINK1__ gene in a cohort of Brazilian patients with EOPD. Sixty consecutive familial or sporadic EOPD

Resource use and costs in a Swedish coho
✍ Peter Hagell; Sara Nordling; Jan Reimer; Martin Grabowski; Ulf Persson 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

We estimated resource use and costs in patients with Parkinson's disease (PD), thereby providing baseline data for future economic evaluations of therapeutic interventions. Data were collected from medical records of a South Swedish cohort of 127 PD patients during 1 year (1996) and a mailed questio

A novel LRRK2 mutation in an Austrian co
✍ Dietrich Haubenberger; Silvia Bonelli; Christoph Hotzy; Petra Leitner; Peter Lic 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract To investigate the frequency of mutations in the Leucine‐Rich Repeat Kinase 2 gene (__LRRK2__) in a sample of Austrian Parkinson's disease (PD) patients, we sequenced the complete coding region in 16 patients with autosomal dominant PD. Furthermore, we sequenced exons 31, 35, and 41 add

Predictors of health care use in patient
✍ Angela G. E. M. de Boer; Mirjam A. G. Sprangers; Hans D. Speelman; Hanneke C. J. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 2 views

PURPOSE: To predict health care use in patients with Parkinson's disease. METHODS: The health care use of 235 patients with Parkinson's disease was studied twice over the course of 1 year. Use consisted of visits to the neurologist and general practitioner (GP) and use of a physiotherapist, a psych